<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03741478</url>
  </required_header>
  <id_info>
    <org_study_id>075/2017</org_study_id>
    <nct_id>NCT03741478</nct_id>
  </id_info>
  <brief_title>Intranasal Insulin and Olanzapine Study in Healthy Volunteers</brief_title>
  <acronym>INI/OLA</acronym>
  <official_title>Effect of Antipsychotics on Central Insulin Action in Relation to Glucose Metabolism and Cognition in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre for Addiction and Mental Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre for Addiction and Mental Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Antipsychotic (AP) medications are considered to be the gold standard treatment for psychotic
      disorders including schizophrenia. However, APs have also been commonly associated with
      serious metabolic adverse effects including weight gain and Type 2 Diabetes, with younger
      populations disproportionately affected. In addition, young individuals treated with these
      agents have also been found to be at high risk for glucose dysregulation, including higher
      rates of prediabetes, with significant associations found between AP use and insulin
      resistance. Due to the concerning prevalence of these AP metabolic effects, it becomes
      important to further elucidate the mechanisms underlying AP effects on glucose metabolism,
      which are still poorly understood. One potential underlying mechanism is insulin which has
      been found to regulate hepatic (liver) glucose production through insulin receptors in the
      brain. These insulin receptors also play a role in neuronal growth and memory, or more
      broadly, cognition. Preliminary data in rat models has demonstrated that the AP olanzapine
      (OLA) inhibits the ability of a central insulin stimulus (acting at the level of the brain)
      to decrease endogenous glucose production (EGP), making this mechanism a prime target to
      translate from rodent models to human research. Furthermore, intranasal insulin (INI)
      administration (an analogous central insulin stimulus) has been repeatedly associated with
      improved cognitive performance for verbal memory and visuospatial functions in humans. Given
      these findings and with the goal of translational research, the present study will
      investigate OLA's effects in healthy human volunteers including: (a) the ability of INI to
      reduce EGP during a pancreatic euglycemic clamp (PEC; a glucose metabolism and insulin
      procedure); and (b) the ability of INI to improve cognitive performance. More specifically,
      the present study hypothesizes that:

        1. INI will be associated with a decrease in EGP relative to intranasal placebo (INP) as
           measured by the PEC. This effect will be inhibited if OLA is co-administered.

        2. OLA administration will be associated with decrements in cognitive measures (i.e.,
           visuospatial, and verbal memory) as compared to placebo (PL). Additionally, OLA
           co-administration will block the beneficial effects of INI on cognition previously
           supported by other studies.

        3. INI will result in adaptive changes in neurochemical and neurohemodynamic measures as
           studied using MRI imaging techniques.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of the study is to examine whether a single dose of OLA given to young
      healthy volunteers during PECs can inhibit the activity of a central insulin stimulus (i.e,
      INI) to reduce endogenous glucose production. Secondarily, in an exploratory arm, this study
      seeks to examine whether a single dose of OLA can inhibit improvements associated with INI
      administration on specific cognitive domains (visuospatial, and verbal memory). Further, the
      study will also explore the effects of insulin and OLA on neurochemical and neurohemodynamic
      measures obtained through MRI imaging techniques.

      To accomplish these objectives, this study will have two separate and parallel arms - a
      metabolic PEC arm to study the primary hypothesis, and an MRI imaging and cognitive testing
      arm to study the two secondary hypotheses.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 22, 2019</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This study will follow a single-blind, crossover design wherein each participant will participate in all of the 4 possible treatment combinations (intranasal insulin or intranasal placebo, olanzapine or placebo) including:
Intranasal placebo and placebo
Intranasal placebo and olanzapine
Intranasal insulin and placebo
Intranasal insulin and olanzapine</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Participants will be masked to:
Knowing whether they were assigned to the olanzapine or placebo conditions
Knowing whether they were assigned to the intranasal insulin or intranasal placebo conditions.
Investigators will only be masked to the randomization of placebo or olanzapine for the participants, but will know whether the participant receives intranasal insulin or intranasal placebo.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Endogenous Glucose Production: Pancreatic Euglycemic Clamp Experiments</measure>
    <time_frame>Visits 1-4 (16-24 weeks) for the metabolic arm</time_frame>
    <description>Participants in the metabolic arm will complete four pancreatic euglycemic clamp (PEC) procedures. The PEC will measure changes in the ability of INI to reduce endogenous glucose production (EGP; the primary outcome measure) relative to INP and the presence of OLA (or PL). EGP will be reflected in dextrose infusion rates (InFR) measured during the PEC across treatment conditions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Cognitive Functioning: MRI scans across the 4 visit conditions</measure>
    <time_frame>Visits 1-4 (9-18 weeks) for the cognitive arm</time_frame>
    <description>Participants in the cognitive arm will complete 4 MRI scans that will include intra-scanner testing to assess changes in cognitive functioning across randomization conditions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral Glucose Tolerance Test</measure>
    <time_frame>Screening Visit 2 (1-2 weeks) for both arms</time_frame>
    <description>Following collection of baseline samples, a standard glucose drink (75mg) is given orally, and a blood sample of insulin and glucose is obtained 2 hours after the glucose drink is administered. Serums which will be collected during this procedure include fasting glucose and fasting insulin related to weight gain and glucose metabolism.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Healthy Controls</condition>
  <arm_group>
    <arm_group_label>Metabolic Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm includes a screening visit 1 and screening visit 2 to assess eligibility.
This arm then includes the pancreatic euglycemic clamp procedure at visits 1 to 4. Visits 1 to 4 each consist of 3 days (day 0, day 1, and day 2).
Olanzapine 2.5mg (or placebo) will be administered in doses of 5mg on day 0, 7.5mg on day 1, and 10mg on day 2.
Day 2 consists of the final dose of olanzapine (or placebo) and the pancreatic euglycemic clamp procedure and other assessment procedures.
On day 2, the participant is also randomized to and administered either intranasal insulin/Insulin Lispro 100 UNT/ML (or saline placebo) during the pancreatic euglycemic clamp procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cognitive and MRI Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm includes a screening visit 1 and screening visit 2 to assess eligibility. This arm includes an MRI scan and cognitive testing at visits 1 to 4. Visits 1 to 4 each consist of 3 days (day 0, day 1, and day 2).
Olanzapine 2.5mg (or placebo) will be administered in doses of 5mg on day 0, and 10mg on day 1. Cognitive testing and MRI scanning then occur on day 2. On day 2, the participant is also randomized to and administered either intranasal insulin/Insulin Lispro 100 UNT/ML (or saline placebo) prior to conducting the MRI imaging and cognitive testing.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OLANZapine 2.5 MG</intervention_name>
    <description>Olanzapine capsules (2.5mg) will be administered with the following dosing schedules for each arm:
Metabolic arm - 5mg on Day 0, 7.5mg on Day 1, and 10mg on Day 2
Cognitive arm - 5mg on Day 0, 10mg on Day 1</description>
    <arm_group_label>Cognitive and MRI Arm</arm_group_label>
    <arm_group_label>Metabolic Arm</arm_group_label>
    <other_name>Mylan-Olanzapine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules visually identical to those containing olanzapine will be administered according to the same dosing schedule for each arm.</description>
    <arm_group_label>Cognitive and MRI Arm</arm_group_label>
    <arm_group_label>Metabolic Arm</arm_group_label>
    <other_name>Olanzapine Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Lispro 100 UNT/ML</intervention_name>
    <description>Intranasal insulin spray (or placebo) will be administered on day 2 for each arm.
For the metabolic arm: 40 IU of intranasal insulin lispro will be administered at timepoint 0 during the pancreatic euglycemic clamp procedure.
For the cognitive arm: 160 IU of intranasal insulin lispro will be administered at about 11 am on day 2 prior to the MRI imaging and cognitive testing procedures.</description>
    <arm_group_label>Cognitive and MRI Arm</arm_group_label>
    <arm_group_label>Metabolic Arm</arm_group_label>
    <other_name>Intranasal Insulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Placebo saline spray visually identical to the intranasal insulin spray will be administered on day 2 for each arm according the same dosing schedules.</description>
    <arm_group_label>Cognitive and MRI Arm</arm_group_label>
    <arm_group_label>Metabolic Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy non-obese volunteers

          -  Age: 17 to 45

        Exclusion Criteria:

          -  History of current or past psychiatric illness (according to the Mini International
             Neuropsychiatric Interview [MINI])

          -  Left-handedness (only for the cognitive and MRI arm)

          -  Pre-diabetes or diabetes (fasting glucose â‰¥6.0mmol/L or use of anti-diabetic drug);

          -  Evidence of impaired glucose tolerance on screening OGTT

          -  Family history of diabetes

          -  Use of weight reducing agents or other medications based on the discretion of the PI

          -  History of liver disease or AST&gt; 2 times upper limit of normal

          -  History of kidney disease

          -  Major medical or surgical event within the last 6 months

          -  Any condition that interferes with safe acquisition of MRI data such as metal
             implants, pacemakers, cochlear implants, claustrophobia, etc. (only for the cognitive
             and MRI component)

          -  Pregnancy and/or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margaret K Hahn, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre for Addiction and Mental Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Satya Dash, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Margaret K Hahn, PhD, MD</last_name>
    <phone>416-535-8501</phone>
    <phone_ext>34368</phone_ext>
    <email>margaret.hahn@camh.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mahavir Agarwal, MBBS, MD</last_name>
    <phone>416-535-8501</phone>
    <phone_ext>30546</phone_ext>
    <email>mahavir.agarwal@camh.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Health Network - Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Center for Addiction and Mental Health</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 1R8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margaret Hahn, MD, PhD</last_name>
      <phone>416-535-8501</phone>
      <phone_ext>34368</phone_ext>
      <email>margaret.hahn@camh.ca</email>
    </contact>
    <contact_backup>
      <last_name>Mahavir Agarwal, MD, MBBS</last_name>
      <phone>416-535-8501</phone>
      <phone_ext>30546</phone_ext>
      <email>mahavir.agarwal@camh.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Margaret Hahn, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mahavir Agarwal, MD, MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>November 3, 2018</study_first_submitted>
  <study_first_submitted_qc>November 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2018</study_first_posted>
  <last_update_submitted>January 6, 2020</last_update_submitted>
  <last_update_submitted_qc>January 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre for Addiction and Mental Health</investigator_affiliation>
    <investigator_full_name>Margaret Hahn</investigator_full_name>
    <investigator_title>Clinician Scientist</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin Lispro</mesh_term>
    <mesh_term>Olanzapine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

